Features of Fecal and Colon Microbiomes Associate With Responses to Biologic Therapies for Inflammatory Bowel Diseases: a Systematic Review

We performed a systematic review of changes in fecal and colon microbiomes of patients with inflammatory bowel diseases (IBD) receiving treatment with monoclonal antibodies against tumor necrosis factor (TNF), integrins, or cytokines. We explored associations among microbiome composition and functions (at baseline and throughout the treatment) and therapy-related outcomes to determine whether colon or fecal microbiomes might be used as biomarkers of response to therapy.

Source: Clinical Gastroenterology and Hepatology - September 13, 2019 Category: Gastroenterology Authors: Maria Manuela Estevinho, C átia Rocha, Luís Correia, Paula Lago, Paula Ministro, Francisco Portela, Eunice Trindade, Joana Afonso, Laurent Peyrin-Biroulet, Fernando Magro, GEDII (Portuguese IBD Group) Source Type: research